Why now?
Large pharma: Scouting next-generation modalities to novel targets and combination therapies, enhance your strides in the race for first- and best-in-class with improved tissue-specificity, delivery and efficacy
Biotech: Wanting to understand pharma's targets of interest, extend cash flow runway, and validate pipelines and platforms
This specialized format and elite attending audience ensures visibility and insights across CVRM deal-making, market dynamics, and future runway.
This summit offers the most efficient use of your partnering conference time:
Engage in direct, face-to-face conversations with dozens of relevant prospective partners
Gain valuable feedback and delve into in-depth discussions with key decision-makers
Cut through the noise of larger, more diverse conferences and effectively differentiate your company and technology
All the while, gain valuable market insights into future dealmaking trends and how this dynamic community will drive significant clinical success across the CVRM landscape.
"This event was more focused than BIO. Plenty of opportunities to bump into people and many of the pharma companies made themselves available. We felt that we got much more traction at this event than at BIO"
CEO attendee, ADC & Radiopharmaceuticals Pharma Partnering Summit, September 2024
Partnering Format
More Targeted
Connect with a targeted critical mass of decision-makers aligned with your strategic and scientific goals. Increase hit rate and efficiency of networking with an entire conference of viable partners. From preserving muscle mass with novel targets to pioneering first-in-class modalities with improved efficacy, safety, and dosing duration.
EARLIER OPPORTUNITY
Build new and stronger relationships with key pharma and investor contacts to emphasize your company's competitive edge. Engage face-to-face and have time to schedule follow-up chats without the intensity of a larger crowd.
*The average number of meetings that result in follow-up after the conference is 4.
WITH SCIENTIFIC INSIGHTS
From improving metabolic disease management and risk with tissue-selective RNA-based and oligonucleotide therapies to next-generation small molecules and biologics with improved drug-like properties. Position your company at the front of scientific innovation to show where you add value, as pharma and investors gain strategic insights.
Looking to invest, acquire, license, or partner?
EVENT IN NUMBERS
Laying enabled partnering on top of hyper-relevant scientific discussion so that pharma can contextualize and compare, and biotech can have guaranteed face-to-face meetings with the right, current contacts.
C-level or senior level attendees from over 60 companies
private meeting slots across two days
networking, from candid interactions to pre-scheduled meetings
alignment with all attendees increasing hit-rate and efficiency of networking
Testimonials
The focused niche really increased the impact for us overall. Thanks for including us in the program
David Dowling, Global Search & Evaluation Lead, Pharma Partnering, Roche
It was stellar; I heard this sentiment echoed throughout. We appreciated the focused yet expansive discussions, and talks in a more intimate setting allowing for easier networking, too
Kilang Yanger, Associate Director, Business Development Seach & Evaluation, BMS
I thought it was fantastic - operationally excellent and thoughtfully designed
Albert Hsia, Executive Director, Business Development, Merck
It was a great group of high-quality companies/people in the perfect setting
Melissa Conner, Senior Director of Acquisitions & Licensing, J&J